[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 2001

Child Advocacy and Robust Community-Centered Research

Author Affiliations

Not Available

Arch Pediatr Adolesc Med. 2001;155(4):438-439. doi:10.1001/archpedi.155.4.438

DOES THE DRUG piracetam improve the cognition of children with Down syndrome?1 In contrast with exuberant testimonials appearing on television and the Internet, Lobaugh et al2 found no substantial benefit in their randomized controlled study. Despite the trial's relatively small cohort size, its rigorous double-blinded crossover design should earn our respect, while their findings (especially of undesirable behavioral effects) should temper our enthusiasm for piracetam markedly.

First Page Preview View Large
First page PDF preview
First page PDF preview
×